Breakthrough Science Requires Collaboration with Other Leaders in Gene Modification and Gene Therapy

Scripps Research, La Jolla, CA

Enochian and Scripps Research, one of the most notable medical research institutions in the world, entered a fee-for-service agreement to conduct a series of syngeneic and humanized mice studies. The research is being conducted in the laboratory of Phillippe Gallay, PhD, Professor of Immunology in the Scripps Research Department of Immunology and Microbiology. We believe this agreement will help advance the pre-clinical work necessary to obtain an Investigational New Drug application (IND) with the FDA and provide further valuable insights into the HIV program.

Dong Sung An, MD, PhD, Professor at UCLA

Enochian also entered into an R&D agreement with Dong Sung An, MD, PhD, professor at UCLA. The team focuses on employing genetic modification techniques to make the human population resistant to HIV. Professor An will support the company’s pre-clinical development program, including but not limited to viral vector design. His laboratory will also conduct studies in cells transduced with genes to protect them from infection for HIV. UCLA is one of the leading academic centers in the field of HIV/AIDS research. Dr. An’s prior work for vector designs for an efficient stem cell gene modification to develop anti-HIV will provide valuable insights to Enochian HIV program.

Hitachi Chemical Advanced Therapeutics Solutions (HCATS)

Enochian and HCATS (ex-PCT Cell Therapy Services), one of the world’s largest cell therapy contract development and manufacturing organization (CDMO), signed an agreement to perform a manufacturing assessment of Enochian Biosciences’ ENO-1001 in support of Enochian’s efforts to develop the CMC section of ENO-1001. This agreement allows Enochian Biosciences to leverage HCATS’ extensive experience in cell therapy development and manufacturing technology and wide-ranging manufacturing locations and we believe will allow us to provide clinical supply for our clinical trials in the future.

Katherine Bar, MD, Professor and Director of the Center for AIDS Research, University of Pennsylvania

Dr. Bar is a leading HIV clinician and researcher. Her laboratory developed a Simian-Human Immunodeficiency Virus (SHIV) used in important non-human primate studies. Dr. Bar is collaborating on the study of Enochian’s preventive and therapeutic HIV vaccine studies in non-human primates, including providing the SHIV to be used.

Timothy Block, PhD, the Hepatitis B Foundation and the Baruch S. Blumberg Institute

Dr. Block is the Co-Founder and President of both the Hepatitis B Foundation and the Blumberg Institute. He is one of the top thought leaders and researchers in the field of hepatitis B virus (HBV). Enochian is collaborating with Dr. Block and laboratories at the Blumberg Institute to evaluate the mechanism of action of our potential HBV treatment or cure.